ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
PR Newswire•08/10/2026•09:00 ET
1
Key Highlights
- ➤$86.6 million PIPE extends expected cash runway into 2029
- ➤$70.0 million loan prepayment reduces senior debt principal to $50.0 million
- ➤HCR amendment eliminates $150 million change-of-control payment
- ➤HCR warrant exercise price cut from $3.8130 to $0.10 per share
- ➤Q3 ZYNLONTA net product revenue estimated at approximately $21.0 million
Expert Statements
Ameet Mallik, Chief Executive Officer of ADC Therapeutics
“We are pleased to announce this robust set of improvements to our capital structure which reflect confidence in ZYNLONTA's growth potential from both long-standing and new investors as well as from HCR and our lenders,”
Ameet Mallik, Chief Executive Officer of ADC Therapeutics
“These efforts extend our expected cash runway and increase strategic optionality, as we approach much anticipated LOTIS-7 and MZL data abstracts in early November with presentations in December at the 68th American Society of Hematology Annual Meeting.”
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements PR Newswire
$86.6 Million Private Placement announced, with participation from new and existing investors, extending expected cash runway into 2029
Get started
Create a free account to read the full story.